Q3 EPS Estimate for Contineum Therapeutics Lifted by Analyst

Key Points

• William Blair analysts have raised their Q3 2025 earnings per share estimate for Contineum Therapeutics from ($0.42) to ($0.35), maintaining an "Outperform" rating on the stock.
• Current consensus for Contineum Therapeutics' full-year earnings stands at ($2.01) per share, with the average price target from analysts set at $22.50.
• The company's stock has fluctuated recently, with a twelve-month low of $3.35 and a high of $20.55, currently trading around $6.73.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) - Investment analysts at William Blair boosted their Q3 2025 earnings per share (EPS) estimates for Contineum Therapeutics in a research note issued on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will earn ($0.35) per share for the quarter, up from their previous forecast of ($0.42). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Contineum Therapeutics' current full-year earnings is ($2.01) per share. William Blair also issued estimates for Contineum Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($1.25) EPS and FY2029 earnings at ($1.12) EPS.

Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Contineum Therapeutics from $25.00 to $20.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $31.00 target price on shares of Contineum Therapeutics in a report on Thursday, May 15th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $22.50.

Contineum Therapeutics Stock Up 4.4%

Shares of NASDAQ CTNM traded up $0.28 during mid-day trading on Friday, hitting $6.71. 44,530 shares of the company traded hands, compared to its average volume of 131,038. Contineum Therapeutics has a 1 year low of $3.35 and a 1 year high of $20.55. The stock has a market capitalization of $173.59 million, a price-to-earnings ratio of -3.05 and a beta of 1.04. The business has a 50 day moving average of $4.72 and a two-hundred day moving average of $5.60.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Deutsche Bank AG acquired a new position in Contineum Therapeutics during the fourth quarter valued at $236,000. Bank of America Corp DE raised its position in Contineum Therapeutics by 63.4% during the fourth quarter. Bank of America Corp DE now owns 9,132 shares of the company's stock valued at $134,000 after buying an additional 3,542 shares during the period. Nuveen Asset Management LLC acquired a new position in Contineum Therapeutics during the fourth quarter valued at $195,000. Barclays PLC raised its position in Contineum Therapeutics by 96.0% during the fourth quarter. Barclays PLC now owns 16,286 shares of the company's stock valued at $239,000 after buying an additional 7,978 shares during the period. Finally, Geode Capital Management LLC raised its position in Contineum Therapeutics by 46.4% during the fourth quarter. Geode Capital Management LLC now owns 188,408 shares of the company's stock valued at $2,761,000 after buying an additional 59,732 shares during the period.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).